An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
作者: Jan-Peer ElshoffWilli CawelloJens-Otto AndreasFrancois-Xavier MathyMarina Braun
作者单位: 1UCB Pharma
刊名: Drugs, 2015, Vol.75 (5), pp.487-501
来源数据库: Springer Nature Journal
DOI: 10.1007/s40265-015-0377-y
英文摘要: Abstract(#br)This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D3/D2/D1 dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson’s disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a transdermal patch providing continuous drug delivery over 24 h, with a plasma concentration profile similar to that of administration via continuous intravenous infusion. Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose. Following a single administration of rotigotine transdermal system (24-h patch-on period), most of the absorbed drug is eliminated in urine and feces as sulphated and...
全文获取路径: PDF下载  Springer Nature  (合作)
分享到:
来源刊物:
影响因子:4.633 (2012)

×